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INTRODUCTION	  
Caspase-1 is an enzyme that is overactive in 
autoimmune and autoinflammatory diseases 
such as Alzheimer’s disease, Crohn’s disease, 
Rheumatoid Arthritis, and more.1 The enzyme is 
responsible for the cleavage of pro-interleukin-
1β into the cytokine interleukin-1β (IL-1β). The 
abundance of IL-1β leads to the inflammatory 
symptoms of the aforementioned diseases.1 It 
does so by inducing gene expression 
of inducible nitric oxide synthase (iNOS) in glial 
cells, thus producing nitric oxide (NO)2.  
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NO has a regulatory effect on immune response, 
in that lower concentrations of NO limits the 
inflammatory response and, in higher 
concentrations, it results in observed 
inflammatory symptoms.2,3 An effective 
inhibitor for caspase-1 will cause a decrease in 
the concentration of IL-1β as the activity of the 
enzyme decreases, leading to a reduction in 
inflammatory symptoms. 
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are the current drug options for treating some 
auto-inflammatory diseases. Most NSAIDs have 
gastrointestinal, renal, and hepatic side effects.2 
Recent research has revealed that an inhibitor 
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containing a nitric oxide (NO) or nitroxyl 
(HNO) donating group could avoid the side 
effects caused by currently available NSAIDs.2 
Caspase-1 is known to have an active site thiol 
group, which makes it susceptible to oxidation 
by NO.  A small molecule based on a known 
caspase-1 inhibitor with a nitrosocysteine 
appended on was designed and synthesized to 
look at the effect of NO donation on caspase-1, 
similar to the NSAID-NO inhibitors mentioned 
above. 
 
Two parts are necessary for the analysis of the 
activity of caspase-1. First, a substrate is needed 
to simulate the environment necessary for the 
overactivity of caspase-1 and to produce a 
measurable quantity of activity. Second, an 
inhibitor must be used to decrease the activity of 
the enzyme through competitive, non-
competitive, or mixed inhibition. Since the 
active site would be directly targeted, the 
inhibitor will likely be competitive and 
reversible. In this case, the NO group is 
presumably donated from the inhibitor to a thiol 
group located on the active site of caspase-1 (a 
process called trans-nitrosation), modifying the 
active site and blocking nucleophilic attack on 
the substrate by the active site thiol and 
subsequent cleavage of the substrate.  
	  
METHODS	  
	  
General	  Methods: All reagents were purchased 
from commercial sources and used as received. 
Caspase-1 and fluorogenic peptide substrate for 
caspase-1 (WEHD-AMC) were purchased from 
Enzo Life Sciences. NMR spectra were taken on 
a Bruker 300 MHz spectrometer. Enzyme assays 
were performed in 96-well plate format on a 
BioTek Synergy H1 multimodal plate reader. All 
purifications were done using silica gel and 
gradients of dicholormethane/methanol or 
hexanes/ethyl acetate as detailed below. 
 
Route	  A:	  
Preparation of A2: 2-phenoxybenzoic acid (100-
200 mg) was added to a vial with a stir bar. 
Approximately 1 mL of thionyl chloride was 
added to the vial and covered with parafilm. The 
reaction vial was then placed in a hot oil bath at 
60˚C and left for the mixture to reflux for 24 
hours. After 24 hours, the vial was removed 
from the hot oil bath and left to stir for a 
minimum of five days. Once the reaction was 
completed, as determined through TLC (95% 
DCM:5% MeOH), the product was extracted 
four times using sodium bicarbonate and dried 
with sodium sulfate. The product was washed 
with dichloromethane and solvent was removed 
with a rotary evaporator; washing was repeated 
twice more. Observations: Yellow, grainy solid 
product. Yield of A2: 77.9%. A2 1H NMR (300 
MHz, CD3OD) δ: 7.91 (d, 2H), 7.19-7.47 (m, 
16H), 6.92-7.02 (t, 3H). 
 
Preparation of A3: Crude A2 product (0.1 M in 
dry DCM) was reacted under nitrogen with 1.2 
equivalents of S-trityl-cysteine, and excess 
DMAP. The reaction was left to stir for a 
minimum of two days and the reaction was 
determined complete through use of TLC (95% 
DCM:5% MeOH). The product was extracted 
three times using 1 M hydrochloric acid. Solvent 
was removed with a rotary evaporator. The 
desired product was isolated through column 
chromatography using DCM and methanol (0%-
7%) and checked for purity using 1H NMR in 
CD3OD. Observations: Crude product: tar-like, 
off-white substance. Isolated product: pale, 
yellow solid. Yield of A3: 7.62%. 1H NMR (300 
MHz, CD3OD) δ: 8.03 (d, 1H), 7.51 (t, 1H), 
7.26-7.36 (m, 12H), 7.16-7.26 (m, 12H), 7.09 (d, 
2H), 6.95 (d, 1H), 4.57 (t, 1H), 2.66 (m, 2 H). 
 
Route	  B:	  
Preparation of B1: 2-phenoxybenzoic acid (100-
200 mg) was combined with 1.5 molar 
equivalents of (L)-S-tritylcysteine amide, 1.5 
molar equivalents of EDC, 1 molar equivalent of 
HOBT, 4-8 molar equivalents of DMAP and 
dissolved in DCM (0.1 M equivalent). The 
reaction was left to stir at room temperature for 
24 hours. The reaction was monitored via TLC 
(1:1 Hexanes:EtOAc). The product was 
extracted four times with 1 M HCl, washed once 
with saturated NaCl, and dried over Na2SO4. 
Solvent was removed with a rotary evaporator. 
Column chromatography was used to isolate the 
product using a 2:1 Hexanes:EtOAc first to 
remove all highly mobile byproducts, and then 
followed by 1:1 Hexanes:EtOAc to remove the 
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desired product from starting material. The 
fractions containing the product were combined 
and solvent was removed with a rotary 
evaporator. An 1H NMR in CDCl3 was taken to 
check for purity. Observations: Off-white solid. 
Yield of B2: 55% 1H NMR (300 MHz, CDCl3) 
δ: 8.26 (d, 1H), 8.17 (dd, 1H), 7.39-7.48 (dt, 
1H), 7.36 (d, 3H), 7.33 (d, 4H), 7.25 (d, 1H), 
7.28 (d, 1H) 7.18 (s, 3H), 7.16 (s, 5H), 7.12 (d, 
2H), 6.99 (d, 2H), 6.89 (d, 1 H), 6.19 (s, 1H), 
5.45 (s, 1H), 4.44 (q, 1H), 2.82 (q, 1H), 2.53 (q, 
1H). 
 
Preparation of B2: A mass of B1 was diluted 
with 1 mL of DCM and chilled on ice. A 
solution of 4:2:1 by volume of trifluoroacetic 
acid (TFA):DCM:triisopropylsilane (TIPS) was 
made for the reaction. B1 had a final 
concentration of 0.1 M in the solution. The 
TFA:DCM:TIPS solution was added dropwise 
to B1 and left to stir for an hour. Deprotection is 
indicated by the solution turning a bright yellow, 
followed by turning clear, indicating completion 
of the reaction. The solution was then washed 
with DCM and rotovapped to remove the TFA 
and repeated twice more. The product was dried 
under vacuum to remove all TIPS. Removal of 
excess TIPS was checked with 1H NMR in 
CDCl3. After confirmation of all TIPS being 
removed, the product was isolated using column 
chromatography starting with 100% DCM and 
finishing with 95% DCM: 5% MeOH. The 
fractions containing the product were combined 
and solvent was removed with a rotary 
evaporator. An NMR in CDCl3 was taken to 
check for purity. The product was dried under 
vacuum to remove all solvents before finally 
being dissolved in DMSO to make a 20 mM 
solution. The solution was stored in the freezer 
at 0˚C. Observations: White solid. Yield of B2: 
10% with 95% purity. 1H NMR (300 MHz, 
CDCl3) δ: 8.69 (d, 1H), 8.23 (dd, 1H), 7.37-7.51 
(m, 3H), 7.16-7.30 (m, 2H), 7.10 (d, 2H), 6.94 
(d, 1H),  6.47 (s, 1H), 5.46 (s, 1H), 4.94 (m, 1H), 
3.26 (m, 1H), 2.70 (m, 1H). 
 
Preparation of B3: At least 50 µL of a 0.2 M 
NaNO2 in 0.5 M HCl solution was made using a 
small mass of NaNO2. Equivalent volumes (50 
µL) of 20 mM B2 and 0.2 M NaNO2 in 0.5 M 
HCl were reacted together in a centrifuge tube 
and covered with foil to reduce the reaction’s 
exposure to light. The reaction was left for 30 
minutes. The nitrosylated B3 was diluted to 
make 500, 250, and 50 µM dilutions in DMSO. 
 
Caspase-1 inhibition assay of B3: The inhibition 
assay was done at 100 µL total volume and in 
triplicate in a 96-well plate format. The assay 
was monitored at room temperature for 60 
minutes in HEPES buffer (50 mM HEPES, 10 
mM NaCl, 0.5% CHAPS, 1 mM EDTA, 10% 
glycerol, 10 mM DTT ph 7.4). Caspase-1 was 
activated with 100 µM DTT on ice for 30 
minutes and held constant for all assays with 5 
nM caspase-1. The substrate WEHD-AMC was 
held constant for all assays at 10 µM. After 
enzyme activation, the inhibitor and caspase-1 
were left to incubate for 30 minutes before the 
addition of WEHD-AMC substrate. The 
reactions were monitored immediately after the 
addition of the WEHD-AMC to the wells. The 
percent activities of caspase-1 were calculated 
from the control screening of caspase-1 
containing no inhibitor. The concentration of 
product, 7-amino-4- methylcoumarin (AMC) 
was calculated from the corresponding standard 
curve. Percent activity versus inhibitor 
concentration was plotted in Origin and fit using 
a non-linear curve fit to approximate IC50 values 
of B3 from the dose-response curve.  
	  
RESULTS	  
An initial synthesis (Route A) was proposed to 
make a small molecule nitrosocysteine inhibitor, 
starting with 2-phenoxybenzoic acid. Generally, 
the synthesis was ineffective and the final 
product could not be obtained for testing with 
caspase-1. Because of this, a second, more 
efficient synthesis (Route B) was developed that 
yielded a nitrosocysteine-containing caspase-1 
inhibitor.  Route A is shown in Figure 1.  
 
The first step began with 2-phenoxybenzoic 
acid, A1. The reaction was refluxed with thionyl 
chloride to generate A2, an acid chloride. In the 
first attempt, a minor extraction was performed 
with HCl, and the reaction yielded a dark brown, 
grainy product. In the second reaction, A2 was 
fully extracted, resulting in the pale yellow solid 
seen in this and the remaining two attempts. The 
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crude A2 product was reacted with (L)-S-
tritylcysteine, along with TEA and DMAP, and 
dissolved in DCM to form A3. The product A3 
was successfully made in all the attempted 
reactions; however it was isolated only once. 
The yield was so small that the next step could 
not be taken. Only the first two steps of the 
Route A synthesis were completed: the 
substitution of the carboxylic acid to form A2, 
and the addition of S-trityl-cysteine to the acid 
chloride to form A3.  
 
 
 
Figure 1. Route A synthesis of nitrosocysteine inhibitor using (L)-S-tritylcysteine.  
 
 
Figure 2. Route B synthesis of nitrosocysteine inhibitor using (L)-S-tritylcysteine amide.  
 
A second synthesis was proposed using (L)-S-
tritylcysteine amide instead of (L)-S-
tritylcysteine. Route B is shown in Figure 2. 
The reaction begins again with 2-
phenoxybenzoic acid, A1. However the 
carboxylic acid is directly amidated using (L)-S-
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tritylcysteine amide with EDC, HOBT, and 
DMAP dissolved in DCM. The product B1 was 
made successfully in multiple reactions. After a 
small scale reaction was completed with high 
success, a scale-up reaction was done to 
generate a larger amount of material to use for 
the deprotection step. The S-trityl group on B1 
was initially deprotected using only TFA (about 
1 mL for 10 mg of B1) and no DCM or TIPS. 
However, the product could not be isolated from 
the removed trityl group. A second attempt was 
made using a 4:2:1 solution of TFA:DCM:TIPS. 
The first attempt with the 4:2:1 solution of 
TFA:DCM:TIPS was unsuccessful and the 
product could not be isolated from the excessive 
amount of TIPS. Another attempt was made 
using less of the 4:2:1 solution of 
TFA:DCM:TIPS. The reaction was completed 
within an hour and the final B2 product was 
isolated using column chromatography. Enough 
material was made to save and use in the final 
step. The nitrosylation of B3 occurred with 
NaNO2 dissolved in 0.5 M HCl and was tested 
against caspase-1. Preliminary biochemical 
results showed B3 displayed an IC50 5.5 ± 2 µM 
(Figure 3). Additional studies need to be 
completed to determine the mechanism of 
inhibition prior to precise determination of IC50 
values.  
	  
	  
 
Figure 3. IC50 curve of B3 showing reduction of % activity of caspase-1 versus concentration of inhibitor (µM). 
 
 
DISCUSSION	  
 
As stated earlier, the Route A synthesis was 
unsuccessful, mainly due to the unsuccessful 
formation of A3. The biggest issue is that A3 
and the (L)-S-tritylcysteine had so similar an Rf 
value that A3 could not be removed from the 
column without contamination from the cysteine 
starting material. The reason the yield had been 
so small (<10%) in the second attempt of 
isolating A3 was because most of the fractions 
contained the (L)-S-tritylcysteine. There were 
also multiple side products from the reaction 
indicating that the reaction was not entirely 
efficient, despite having gone to completion.  
 
The failure to produce a workable amount of A3 
after multiple reactions led to a redesign of the 
synthesis. Instead of having A1 react with 
thionyl chloride to make an acid chloride before 
adding the cysteine, the synthesis was shortened 
by adding the (L)-S-tritylcysteine amide directly 
to A1. Recognizing that the free carboxylic acid 
caused a major issue in the isolation of A2, the 
next reaction used an amidated version of the 
cysteine, (L)-S-tritylcysteine amide as starting 
5
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material. The amido group is less acidic than the 
carboxylic acid, which in turn created a simpler 
separation via silica gel column 
chromatography.  B1 was made easily within 24 
hours and the workup removed excess EDC and 
HOBT from the product. However, it was not 
entirely effective in removing all the cysteine 
starting material. Column chromatography was 
used to isolate the product without 
contamination from either the side products or 
cysteine starting material, as checked by 1H 
NMR. The NMR spectra showed an alkyl peak 
at 4.44 ppm, indicating that the reaction had 
occurred to form B1. After the initial success of 
the reaction on a small scale, the procedure was 
repeated to generate more material to work with. 
The scale-up was successful, pointing to the 
reproducible nature of this pathway. 
 
Deprotection of B1 was first attempted with pure 
TFA without any DCM solvent or TIPS. The 
reaction successfully removed the trityl group, 
as observed by the solution turning a bright 
yellow. However, B2 could not be isolated from 
the removed trityl group through any extraction 
method. With additional research, the 4:2:1 
TFA:DCM:TIPS solution was found and used in 
attempt to deprotect B1 and remove the trityl 
group from the solution.5 TIPS is needed in 
order to remove the deprotected trityl group. 
TFA readily removes the trityl group, turning 
the solution a bright yellow.5 The bright yellow 
color is the trityl cation that was removed in the 
reaction.5 As the TIPS binds to the removed 
trityl cation, the solution becomes clear again, 
indicating the completion of the reaction.5 An 
excess of the solution was used the first time and 
the product was unsalvageable from excess 
TIPS. TIPS has a high boiling point and cannot 
be easily removed through use of a rotary 
evaporator. The reaction was repeated and B2 
was successfully made with about 95% purity of 
B2. Several of the 1H NMR peaks had shifted, 
providing evidence that the trityl group had been 
replaced with hydrogen. For example, the alkyl 
peak that was seen in the NMR for B1 was at 
4.44 ppm, but, in B2, it was observed at 4.94 
ppm. Along with the peak shifts, there was a 
dramatic drop in the number of aromatic 
protons, providing another strong indicator that 
the trityl group had been successfully removed. 
The small yield is primarily due to spillage of 
the dissolved product before it was dried under 
vac; however, there was still enough B2 product 
to use for the next reaction. The 20 mM stock of 
B2 was stored at 0˚C in the freezer and was used 
to test the nitrosylation reaction and the effect of 
NO donation to caspase-1. 
 
The nitrosylation reaction occured 
approximately 30 minutes before it was tested 
against caspase-1. The initial results showed that 
the B3 inhibitor has an IC50 of about 5.5 ± 2 µM. 
This means that the inhibitor is capable of 
reducing caspase-1 activity to 50 % at a 
concentration of 5.5 µM. However, these results 
have not been replicated. The product of the 
nitrosylation reaction in sodium nitrite also 
needs to be quantified, which can be done using 
spectrophotometric methods to determine the 
exact amount of small molecule S-NO inhibitor 
we are starting with. After presenting more 
evidence that the B3 inhibitor is working and 
reducing caspase-1 activity, Michaelis-Menten 
kinetics of the inhibitor will be studied along 
with reversibility. 
 
A small molecule nitrosocysteine inhibitor was 
successfully made and tested against caspase-1. 
Initial results have shown successful inhibition 
of caspase-1 using a NO donor small molecule 
inhibitor. Similar small molecules can be 
synthesized and tested against caspase-1 to study 
the effect of inhibition with differeing 
substituents on the aromatic ring. 	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